Dr Akhil Santhosh

Honoured and privileged to receive the ASCO 2025 International Development Education Award (IDEA).. Grateful to all my teachers and mentors who made this happen. @MVRCancerCentre @aiims_newdelhi @oncologistindia @stolaney1 @ConquerCancerFd @ASCO

🚨 New publication alert! 💊Enzalutamide before ☢️¹⁷⁷Lu-PSMA-617 improves OS vs. abiraterone in mCRPC. Stronger PSMA expression, better sequencing and survival! @OncJournal @OncoAlert @APCCC_Lugano @coskunyazgann @hatice_bolek @nahit_sendur @drdeniztural @yekeduz_emre…

Academic read of the day! Crossover in oncology? A concise, open-access, 2-page paper clearly framing when it is is desirable, and when its problematic, by @AlysonHaslam & @VPrasadMDMPH in @Annals_Oncology Seminal 2018 paper and still as relevant! ➡️bit.ly/3TZCOUc

Efficacy and safety of Luteitium therapy rechallenge in MCRPC. Meta analysis . link.springer.com/article/10.100…

Brief Report: Comprehensive Genomic Profiling of Rare Lung Tumors: Adenosquamous Carcinoma and Pulmonary Carcinosarcoma - @JTOonline jto.org/article/S1556-…

Hormonal Factors Predictive of Fertility in Patients with Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy in POSITIVE trial -@myESMO thebreastonline.com/article/S0960-…

Preexisting Depression and Prostate Cancer Survival @JAMA_current jamanetwork.com/journals/jaman…

Another failure for Tigit IMBRAVE 152 read out negative!! oncologypipeline.com/apexonco/5000-…

Finally, a killer application for Y-90 FAPI theranostics? Near complete metabolic responses in 3 patients with treatment refractory solitary fibrous tumors. Ga-68 FAPI had high SUVs (117, 41, 31) with concordant FDG uptake. jnm.snmjournals.org/content/early/… @SNM_MI Wonderful work from…

A proposed treatment algorithm of patients with HR-MDS in 2025 mdpi.com/2072-6694/17/1… #mds @Dr_AmerZeidan

Effectiveness of post-trastuzumab deruxtecan treatments and incidence of interstitial lung disease in HER2-positive metastatic breast cancer: a real-world, observational cohort study☆ - @ESMO_Open esmoopen.com/article/S2059-…

Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer☆ -@ESMO_Open esmoopen.com/article/S2059-…

Tislelizumab plus nab-paclitaxel and cisplatin as induction immunochemotherapy for organ preservation of locally advanced hypopharyngeal squamous cell carcinoma: a single-arm phase II trial - @ESMO_Open esmoopen.com/article/S2059-…

Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multi-Center Retrospective Study - @JTOonline jto.org/article/S1556-…

The emerging role of PARP inhibitors in prostate cancer: A narrative review -@myESMO cancertreatmentreviews.com/article/S0305-…

Intercalated Avelumab plus platinum-based chemotherapy in patients with Extensive-Stage Small-Cell Lung cancer (PAVE): Final Outcome, Immunophenotypic and biomarker analysis of a multi-center phase II Hellenic Cooperative Oncology Group study. ejcancer.com/article/S0959-…

Case of KRAS G12C-Mutated AML Treated With Sotorasib | @JCOPO_ASCO ascopubs.org/doi/10.1200/PO…

A comparison of the risk prediction models PERSARC and Sarculator in patients with localized soft tissue sarcoma of the extremities and trunk wall -@ESMO_Open esmoopen.com/article/S2059-…

Redefining Systemic Therapy Timing in Nasopharyngeal Cancer @JAMAOnc jamanetwork.com/journals/jamao…

Patient Preferences on Clinical Decision Making in Multiple Myeloma | @JCOOP_ASCO ascopubs.org/doi/10.1200/OP…

Afatinib, Dose Reduction, and Pseudo-Acute Kidney Injury | @JCO_ASCO ascopubs.org/doi/10.1200/JC…